The Common Drug Review (CDR) is a single process for undertaking reviews and providing listing recommendations - for new drugs (new chemical entities and new combination products) and new indications for previously approved CDR drugs - to participating federal, provincial and territorial (F/P/T) drug benefit plans in Canada. The goal of the CDR is to objectively assess the clinical and pharmacoeconomic evidence for the newest drug therapies and newest therapies for new indications with old drugs coming to the Canadian market. All jurisdictions are participating except Quebec. The scope of the drugs reviewed may expand in the future. Ontario is an active participant in the CDR process.

New chemical entities or new combination drug products (new drugs), first go through the Common Drug Review (CDR) process, housed at the Canadian Agency for Drugs and Technologies in Health (CADTH) . CADTH is a national body that provides Canada's federal, provincial and territorial health care decisions with credible, impartial advice and evidence-based information about the effectiveness and efficiency of drugs and other health technologies. As part of the CDR process, the Canadian Expert Drug Advisory Committee (CEDAC) , an independent advisory body composed of individuals with expertise in drug therapy and drug evaluation, makes recommendations to each of the participating federal, provincial, and territorial publicly funded drug plans regarding the listings on their formularies.

See also :

• Ontario Drug Benefit (ODB) Review Process
• New Chemical Entity or Combination Drug Products (New Brand Name/Innovator Drug Products)
• Types of Listing Recommendations
• New Drug Funding Program for Cancer Care
• Formulary